BioMedNewsBreaks — Alzamend Neuro, Inc. (NASDAQ: ALZN) Doses First Patient in Phase II Trial for Next-Gen Lithium Therapy AL001

Alzamend Neuro (NASDAQ: ALZN) announced the first patient has been dosed in its Phase II clinical trial of AL001, a novel lithium-based therapeutic designed to treat Alzheimer’s, bipolar disorder, major depressive disorder and PTSD. Conducted at Massachusetts General Hospital, the study in healthy subjects will evaluate AL001’s ability to deliver lithium more efficiently to the brain while minimizing systemic side effects, potentially eliminating the need for therapeutic drug monitoring. 

Backed by promising preclinical data showing improved brain absorption and reduced blood lithium levels, AL001 could mark a breakthrough in neuropsychiatric care. The therapy aims to address long-standing safety challenges associated with traditional lithium salts, which require frequent dosing and monitoring due to a narrow therapeutic window. Topline data from the trial is expected by year-end. 

To view the full press release, visit https://ibn.fm/atoQh 

About Alzamend Neuro 

Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 – a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, salicylate and L-proline, and ALZN002 – a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s by removing beta-amyloid from the brain. The latter is a second-generation active-immunity approach designed to mitigate the disadvantages of approved passive immunity marketed antibody products, particularly by reducing the required frequency and costs of dosing associated with antibody products. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses. 

For more information, visit the company’s website at: https://alzamend.com/

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN